The Role of ADMA in Various Diseases
DOI:
https://doi.org/10.55175/cdk.v50i4.863Kata Kunci:
ADMA, cardiovascular disorders, nitric oxide, risk markerAbstrak
Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of nitric oxide synthase (NOS). Numerous studies have discovered a correlation between high plasma ADMA levels and the development of multiple diseases, including cardiovascular disease, chronic renal disease, diabetes mellitus, liver diseases, preeclampsia, and COVID-19. In addition, ADMA has been established as an independent cardiovascular risk factor. However, the functional interplay between ADMA and nitric oxide (NO)-mediated pathways is poorly understood, leaving the distinction between “risk factor” and “risk marker” unclear. In this review, we provide insights into the current state of knowledge regarding the pathophysiological role of ADMA in various diseases, the relationship between ADMA and endothelial dysfunction, the current analytical techniques used to determine ADMA in body fluids, and the benefits of ADMA-lowering drugs for the prevention of diseases in humans.
Asymmetric dimethylarginine (ADMA) adalah penghambat kompetitif nitric oxide synthase (NOS). Banyak penelitian menemukan hubungan antara peningkatan kadar plasma ADMA dan perkembangan berbagai penyakit, termasuk penyakit kardiovaskular, penyakit ginjal kronik, diabetes melitus, penyakit hati, preeklampsia, dan COVID-19. ADMA juga diidentifikasi sebagai faktor risiko independen untuk penyakit kardiovaskular. Namun, interaksi fungsional antara ADMA dan nitric oxide (NO) belum begitu dipahami, yang menyebabkan tidak jelasnya batasan antara “faktor risiko” dan “penanda risiko”. Tulisan ini membahas pengetahuan terbaru tentang peran patofisiologi ADMA dalam berbagai penyakit, hubungan antara ADMA dan disfungsi endotelial, teknik analisis terkini untuk pemeriksaan kadar ADMA dalam cairan tubuh, serta manfaat obat penurun ADMA untuk pencegahan penyakit pada manusia.
Unduhan
Referensi
Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339(8793):572-5.
Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. The Lancet 2001;358(9299):2096-7.
Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13(2):198-203.
Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyland galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970;245(21):5751-8.
Nakajima T, Matsuoka Y, Kakimoto Y. Isolation and identification of N-G-monomethyl, N-G, N-G-dimethyl- and N-G,N' G-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim Biophys Acta. 1971;230(2):212-22.
Park KS, Lee HW, Hong SY, Shin S, Kim S, Paik WK. Determination of methylated amino acids in human serum by high-performance liquid chromatography. J Chromatogr. 1988;440:225-30.
Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol. 1998;61:65-131.'8. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1(1):65-73.
Liu X, Hou L, Xu D, Chen A, Yang L, Zhuang Y, et al. Effect of asymmetric dimethylarginine (ADMA) on heart failure development. Nitric Oxide 2016;54:73-81.
Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev. 2003;83(1):183-252.
McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J. 1976;154(1):179-84.
Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343 Pt 1(Pt 1):209-14.
Hattori Y, Kasai K, Gross SS. Cationic amino acid transporter gene expression in cultured vascular smooth muscle cells and in rats. Am J Physiol. 1999;276(6):2020-8.
Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem. 1995;117(2):237-8.
Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005;41(3):559-65.
Banjarnahor S, Rodionov RN, König J, Maas R. Transport of L-arginine related cardiovascular risk markers. J Clin Med. 2020;9(12):3975. doi: 10.3390/jcm9123975.
Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003;107(14):1891-5.
Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15(8):901-9.
Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296(2):195-200.
Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33(4):652-8.
Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62(26):2425-30.
Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res. 1998;37(3):667-75.
Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: Role in reduction of plasma nitric oxide level. Heart Vessels 2003;18(4):177-82.
Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23(8):1455-9.
Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109(2):172-7.
MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol. 1994;5(4):1057-65.
Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H, Haller H, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res. 2004;27(3):143-7.
Ruilope LM, Lahera V, Rodicio JL, Romero JC. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens. 1994;12(6):625-31.
Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270(5 Pt 2):845-51.
Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol. 2013;45(1):139-50.
Jacobi J, Tsao PS. Asymmetrical dimethylarginine in renal disease: Limits of variation or variation limits? A systematic review. Am J Nephrol. 2008;28(2):224-37.
Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10(Suppl 1):73-81.
Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): Expression, regulation, and function in the cardiovascular and renal systems. American Journal of Physiology-Heart and Circulatory Physiology 2007;293(6):3227-45.
Chen Y, Li Y, Zhang P, Traverse JH, Hou M, Xu X, et al. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol. 2005;289(5):2212-9.
Chen Y, Park S, Li Y, Missov E, Hou M, Han X, et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 2003;14(3):251-60.
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99(24):3092-5.
Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106(8):987-92.
Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med. 2005;10(Suppl 1):45-8.
Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52(6):1593-601.
Abhary S, Kasmeridis N, Burdon KP, Kuot A, Whiting MJ, Yew WP, et al. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care 2009;32(11):2084-6.
Stojanovic I, Djordjevic G, Pavlovic R, Djordjevic V, Pavlovic D, Cvetkovic T, et al. The importance of L-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy. J Neurol Sci. 2013;324(1-2):40-4.
Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant. 2009;24(6):1884-8.
Liu J, Li C, Chen W, He K, Ma H, Ma B, et al. Relationship between serum asymmetric dimethylarginine level and microvascular complications in diabetes mellitus: A
meta-analysis. Biomed Res Int. 2019;2019:2941861.
Lee W, Lee HJ, Jang HB, Kim HJ, Ban HJ, Kim KY, et al. Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle. Sci Rep. 2018;8(1):2133.
Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R, et al. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl. 2007;13(3):400-5.
Nijveldt RJ, Teerlink T, van Leeuwen PA. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr. 2003;22(1):99-104.
Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World journal of gastroenterology. 2015;21(17):5131-7.
Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007;45(1):62-71.
Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004;41(1):55-9.
Davids M, Richir MC, Visser M, Ellger B, van den Berghe G, van Leeuwen PAM, et al. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism. 2012;61(4):482-90.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH. Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: A case-control study. J Hum Hypertens. 2013;27(1):38-43.
Böger RH, Diemert A, Schwedhelm E, Lüneburg N, Maas R, Hecher K. The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecol Obstet Invest. 2010;69(1):1-13.
Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361(9368):1511-7.
Speer PD, Powers RW, Frank MP, Harger G, Markovic N, Roberts JM. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol. 2008;198(1):112.e1-7.
Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77(8):808-13.
Maas R, Böger RH, Schwedhelm E, Casas JP, López-Jaramillo P, Serrano N, et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia. Jama. 2004;291(7):823-4.
Maeda T, Yoshimura T, Okamura H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in maternal and fetal circulation. J Soc Gynecol Investig. 2003;10(1):2-4.
Saarelainen H, Valtonen P, Punnonen K, Laitinen T, Raitakari OT, Juonala M, et al. Subtle changes in ADMA and l-arginine concentrations in normal pregnancies are unlikely to account for pregnancy-related increased flow-mediated dilatation. Clin Physiol Funct Imaging. 2008;28(2):120-4.
Braekke K, Ueland PM, Harsem NK, Staff AC. Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia. Pediatric Research 2009;66(4):411-5.
Hannemann J, Balfanz P, Schwedhelm E, Hartmann B, Ule J, Müller-Wieland D, et al. Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. Sci Rep. 2021;11(1):9895.
Fang W, Jiang J, Su L, Shu T, Liu H, Lai S, et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med. 2021;163:153-62.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 2020;395(10234):1417-8.
Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003;92(2):226-33.
Hang do TT, Song JY, Kim MY, Park JW, Shin YK. Involvement of NF-κB in changes of IFN-γ-induced CIITA/MHC-II and iNOS expression by influenza virus in macrophages. Mol Immunol. 2011;48(9-10):1253-62.
Liu X, Jana M, Dasgupta S, Koka S, He J, Wood C, et al. Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002;277(42):39312-9.
Chen L, Hsieh MS, Ho HC, Liu YH, Chou DT, Tsai SH. Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis. Nitric Oxide 2004;11(3):228-36.
Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int. 2004;65(5):1664-75.
Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med. 1992;176(2):599-604.
Zhao K, Huang Z, Lu H, Zhou J, Wei T. Induction of inducible nitric oxide synthase increases the production of reactive oxygen species in RAW264.7 macrophages. Biosci Rep. 2010;30(4):233-41.
Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007;15(6):252-9.
Dominic P, Ahmad J, Bhandari R, Pardue S, Solorzano J, Jaisingh K, et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol. 2021;43:101982.
Green SJ. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect. 2020;22(4-5):149-50.
Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4(4):41-51.
Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-98.
Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20(9):2032-7.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-37, 37a-37d.
Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110(4):1457-64.
Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens. 1993;7(2):193-4.
Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Frölich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Letters. 2000;478(1):1-3.
Arancibia-Garavilla Y, Toledo F, Casanello P, Sobrevia L. Nitric oxide synthesis requires activity of the cationic and neutral amino acid transport system y+L in human umbilical vein endothelium. Exp Physiol. 2003;88(6):699-710.
Németh B, Ajtay Z, Hejjel L, Ferenci T, Ábrám Z, Murányi E, et al. The issue of plasma asymmetric dimethylarginine reference range – A systematic review and metaanalysis. PLOS ONE 2017;12(5):e0177493.
Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1-8.
Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851(1-2):42-50.
Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem. 2010;56(1):111-20.
Schwedhelm E. Quantification of ADMA: Analytical approaches. Vasc Med. 2005;10(Suppl 1):89-95.
Tsikas D. A critical review and discussion of analytical methods in the L-arginine/nitric oxide area of basic and clinical research. Anal Biochem. 2008;379(2):139-63.
Weaving G, Rocks BF, Bailey MP, Titheradge MA. Arginine and methylated arginines in human plasma and urine measured by tandem mass spectrometry without the need for chromatography or sample derivatisation. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;874(1-2):27-32.
Martens-Lobenhoffer J, Bode-Böger SM. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851(1-2):30-41.
Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: Regulation and action. Pharmacological Research 2009;60(6):448-60.
Bedford MT, Clarke SG. Protein arginine methylation in mammals: Who, what, and why. Mol Cell. 2009;33(1):1-13.
Thiebaut C, Eve L, Poulard C, Le Romancer M. Structure, activity, and function of PRMT1. Life 2021;11(11):1147.
Dillon MB, Bachovchin DA, Brown SJ, Finn MG, Rosen H, Cravatt BF, et al. Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization. ACS Chem Biol. 2012;7(7):1198-204.
Yin QF, Fu SH, He P, Xiong Y. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: Effects of aminoguanidine. Atherosclerosis 2007;190(1):53-61.
Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertension Research 2005;28(3):255-62.
Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. Journal of Cardiovascular Pharmacology 2005;45(6):525-32.
Jiang JL, Zhang XH, Li NS, Rang WQ, Feng Y, Hu CP, et al. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovasc Drugs Ther. 2006;20(4):281-94.
Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation*. Journal of Biological Chemistry 2006;281(52):39831-8.
Tain YL, Huang LT, Lin IC, Lau YT, Lin CY. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res. 2010;49(4):390-8.
Yang ZC, Wang KS, Wu Y, Zou XQ, Xiang YY, Chen XP, et al. Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: An effect prevented by vitamin E. Cell Physiol Biochem. 2009;24(1-2):115-24.
Lee Y, Mehrotra P, Basile D, Ullah M, Singh A, Skill N, et al. Specific lowering of asymmetric dimethylarginine by pharmacological dimethylarginine dimethylaminohydrolase improves endothelial function, reduces blood pressure and ischemia-reperfusion injury. J Pharmacol Exp Ther. 2021;376(2):181-9.
Strobel J, Mieth M, Endress B, Auge D, Konig J, Fromm MF, et al. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol. 2012;53(3):392-400.
Banjarnahor S, König J, Maas R. Screening of commonly prescribed drugs for effects on the CAT1-mediated transport of L-arginine and arginine derivatives. Amino Acids 2022;54(7):1101-8.
Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med. 2005;10(Suppl 1):49-57.
Yang TL, Chen MF, Xia X, Luo BL, Li YJ. Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol. 2006;62(3):179-84. 105. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr. 2003;89(3):359-63.
Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, et al. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: A pilot study. Am J Nephrol. 2007;27(1):70-4.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
